The Great Debate at the 2019 ACR/ARP Annual Meeting addressed the issue of whether anabolic therapies are appropriate as first-line treatment for glucocorticoid-induced osteoporosis (GIO). The risk is usually defined based on previous fracture history, low T-score, and the presence of multiple risk factors for fracture including smoking, alcohol, or low body weight. Kenneth Saag, MD, presented the pro side while Mary Beth Humphrey, MD, PhD, presented the con side of using anabolic agents for GIO.
Audience members were surveyed on their opinion, with 60% of participants indicating their preference for using anabolic agents including teriparatide as first-line therapy for GIO. It was interesting to see this audience response, as certainly those advocating the use of teriparatide won. I was actually surprised the margin wasnt even greater for the pro side, because clearly anabolic drugs are superior to any antiresorptive agents for fracture protection in high-risk patients, with better bone efficacy data.
The main problem is that there have been no head-to-head trials conducted with fracture reduction as a primary end point for GIO. Several trials have shown bone mineral density (BMD) differences between drugs. Dr Saag noted in his presentation that research has found statistically significantly fewer fractures in patients taking teriparatide, but again, the fracture rate was not indicated as a primary end point in the design of the clinical trial. There also may never be a head-to-head trial for various drugs in GIO, the main reason being obviously the cost of conducting such trials.
Dr Humphrey indicated that patient preference, satisfaction, and adherence should also be taken into account when debating whether anabolic agents should be given to a patient at high risk for GIO, suggesting that some patients will not elect to receive medication delivered by injection. In general, patients dont want an injection when they can be prescribed a pill. From my point of view, the conversation should then shift to which is the best and most effective drug given your risk factors. From there we usually can come to a consensus that may include an anabolic agent. As for medication adherence, a patient who has a history of vertebral fracture and back pain may be more likely to be adherent than someone who is asymptomatic.
What I have found to be the larger issue, not only for payers but also patients, is the cost of the anabolic agents, especially for patients with Medicare who are dealing with the donut hole: those who are unable to use copay cards available to other patients with commercial insurance.
From a pathophysiologic perspective, I like to refer back to studies referenced in the past that point to the foundational effect of an anabolic. Researchers studied the effects of alendronate vs romosozumab in postmenopausal women with osteoporosis in the ARCH trial (Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis, ClinicalTrials.gov Identifier: NCT01631214). This trial found that patients who were treated with romosozumab for 1 year followed by alendronate had a significantly lower risk of fracture compared with patients treated with alendronate alone. The fracture rate in people who had taken romosozumab in the first year was significantly less because of the foundational effect of the drug. The process consists of laying down new bone and then consolidating that new bone formation. That is what we have always had to consider, and this speaks to Dr Humphreys point that you do need to continue on an oral bisphosphonate after romosozumab to consolidate the bone after treatment with an anabolic. I like to tell my patients that this process of building bone is like a spring: first you expand the spring, then you have to prevent bounce back to the set point.
Dr Saag mentioned that he was not advocating anabolic agents as first-line treatment for every patient; these agents should be reserved for high-risk patients. I absolutely agree with him. We do not want to give teriparatide, abaloparatide, or romosozumab to everyone. In some patients, oral bisphosphonates are perfectly appropriate, such as those patients taking steroids.
Another point that was mentioned during the Great Debate was the risk for osteosarcoma, which was mainly derived from rat toxicology data using Fischer rats with open epiphyses their entire lives. The incidence of osteosarcoma was found to be markedly higher at baseline compared with humans. However, this osteosarcoma risk was noted by researchers; a registry was started to examine this link, and a drug length use limitation is imposed with some drugs. The registry is still insufficiently powered, so we are not yet certain that there is no relationship between the drugs and the risk for osteosarcoma. Thus far, various tumor registries in the United States have looked at the incidence of osteosarcoma with teriparatide use and no increased signal has been found.
Currently use of romosozumab is limited to 1 year because the effect tends to wane after 12 months. This is probably because the effect on osteoblasts is so potent that it depletes the osteoblast, and after a year there is nothing left to do. After 1 year, romosozumab becomes an expensive antiresorptive drug. What is further notable is the lack of information on the label about retreatment, as well as the lack of further guidelines about retreatment.
The current gaps in preventing glucocorticoid-induced osteoporosis are similar to those present in preventing postmenopausal osteoporosis. The number of people in whom bone density is being measured and who are being diagnosed with osteoporosis is decreasing. I think some patients may be risk averse because of the issues related to atypical femur fractures and osteonecrosis of the jaw. I think physicians may also be too busy to elevate this issue, even though mortality after hip fracture in women is 20% after one year and in men its 40%.
More broadly speaking apart from GIO, I believe the biggest game changer in osteoporosis research being presented is romosozumab. We now have a new anabolic agent that works differently than teriparatide as a signaling pathway drug. STUCTURE (An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women; ClinicalTrials.gov Identifier: NCT01796301) studied the effect of 1 year of treatment with romosozumab compared with teriparatide on total hip BMD in postmenopausal women with osteoporosis who were previously treated with bisphosphonate therapy. The investigators found a dramatic increase in BMD with romosozumab therapy compared with teriparatide. Importantly, they also conducted finite element analysis at the hip that showed increased hip strength with romosozumab. Given these data, I believe this is the biggest story right now in osteoporosis.
Disclosure: Dr Deal is a speaker and consultant for Radius and Amgen.
- Healthy Men: What women need to know about men's health - Greater Milwaukee Today - November 20th, 2020
- 24 Ways to Increase Penis Sensitivity: Tips, Techniques, and More - Healthline - October 18th, 2020
- Centrapeak Testosterone Booster Review: Is it Better than Others on the Market? - generationiron.com - October 18th, 2020
- Erectile Dysfunction: A Look at the Most Common Causes - Feed Leader - October 10th, 2020
- Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year - BioSpace - October 6th, 2020
- Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020 - Yahoo Finance - October 6th, 2020
- Whats Causing My Low Testosterone? - September 29th, 2020
- Indianapolis Low T Center & Men's Clinic | Sleep Apnea ... - September 29th, 2020
- Could This Device Help Save Covid-19 Patients Before the ICU? - Houstonia Magazine - September 6th, 2020
- Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study - Yahoo Finance - August 17th, 2020
- How can you actively boost your low libido? - Big Think - August 11th, 2020
- Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration - BioSpace - July 30th, 2020
- New Osteoporosis Recommendations From AACE Help Therapy Selection - Medscape - July 25th, 2020
- Hormone therapy no cure-all for 'low T' in ageing men - Health24 - July 20th, 2020
- Strain engineering of the magnetic multipole moments and anomalous Hall effect in pyrochlore iridate thin films - Science Advances - July 20th, 2020
- Does Low Testosterone Cause Night Sweats? - July 7th, 2020
- Treating low testosterone levels - Harvard Health - July 7th, 2020
- Some people who experienced no coronavirus symptoms may now be immune to Covid-19 - here's what the study says - Derry Journal - July 4th, 2020
- AGING: Hormone therapy no cure-all for low T in men - Palm Beach Post - July 2nd, 2020
- COVID 19 Effect on Low T Therapy Market: an Increase in Technology Development Will Heighten Growth of Key Players: AbbVie, Endo International, Eli... - June 23rd, 2020
- Freddy McConnell Gave Birth to His Son. Then His Life Changed. - Esquire - June 18th, 2020
- Low T Therapy Market: What Will Happen to Key Players After COVID 19 Ends: AbbVie, Endo International, Eli Lilly - Cole of Duty - June 9th, 2020
- Ego might drive men to testosterone therapy, but it helps with certain conditions - The Columbus Dispatch - June 8th, 2020
- What Are T-Cells and Can They Protect You from COVID-19? - Labmate Online - June 8th, 2020
- Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update - Yahoo Finance - May 7th, 2020
- COVID-19: T cells offer clues to the potential power of Roche's Actemra - FierceBiotech - May 6th, 2020
- Peek on Low T Therapy Market Future, Extensive Studies and Prediction of Top Manufacturers Condition: AbbVie, Endo International, Eli Lilly - 3rd... - May 6th, 2020
- New clues on how to treat COVID-19 from T cell counts - The Nation - May 3rd, 2020
- Aytu BioScience Signs Development Agreement with Sterling Medical Devices to Advance the Development of Healight as a Potential Coronavirus Treatment... - April 29th, 2020
- Low T Center Is Committed To Meeting The Needs Of Colorado Patients During The COVID-19 Emergency - P&T Community - April 20th, 2020
- Aytu BioScience Announces Positive Results from an Independently Conducted Clinical Study of the Company's Licensed COVID-19 IgG/IgM Point-of-Care... - April 17th, 2020
- The testosterone myth - The Week Magazine - April 12th, 2020
- Low T Therapy Market Industry Analysis, Size, Share, Growth, Trends And Forecast 2020 2024 - Monroe Scoop - March 26th, 2020
- Aytu BioScience Submits Notice of Commercialization to the FDA, Allowing for Company's Distribution of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care... - March 23rd, 2020
- No, not everything about mens sexual behaviour can be explained by testosterone - Scroll.in - March 23rd, 2020
- Letters to the editor - Boston Herald - March 9th, 2020
- Low Testosterone - Symptoms & Treatment | Everyday Health - March 6th, 2020
- Lost revenue from low T fares must be recouped - Boston Herald - March 1st, 2020
- Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management - Carmel... - March 1st, 2020
- Low Testosterone Causes | Everyday Health - February 24th, 2020
- Diagnosis, treatment and how to avoid osteoporosis - The Gazette - January 30th, 2020
- The Signs a Testosterone Booster is Needed - Science Times - January 22nd, 2020
- New Guideline for Testosterone Treatment in Men With 'Low T' - Medscape - January 9th, 2020
- John R. Hampton III, MD, is recognized by Continental Who's Who - PRNewswire - November 27th, 2019
- Low T Specialist - Dallas, TX & Frisco, TX: Men's T-Clinic ... - October 5th, 2019
- Does Insurance Cover Low T Treatment - Mantality Health - October 5th, 2019
- Low Testosterone Therapy (TRT) and Treatment from Low T Center - September 27th, 2019
- Low T Center, 549 East County Line Road, Building 4 Suite D ... - March 31st, 2019
- Low T Symptoms | Low Testosterone | Signs of Low T - March 12th, 2019
- Low T Treatment in Texas & Illinois | SynergenX Health ... - February 18th, 2019
- The Lowdown on Low-T - Discover Health - Rush University ... - February 18th, 2019
- The Low T Scam? - Testosterone Centers of Texas - Low T ... - February 18th, 2019
- Low T 99 - Testosterone Therapy: Bellevue, Seattle, Tacoma ... - December 31st, 2018
- Men, Low T, and the Facts | Lifespan - October 1st, 2018
- Denver Low T Medical Clinic and Testosterone Therapy Center - August 6th, 2018
- You've Heard About "Low T" But What About "Low E"? - April 23rd, 2018
- Low T 99 - 10 Photos - Health & Medical - 1239 120th Ave NE ... - April 23rd, 2018
- Low Testosterone Treatment - Carolina Men's Clinic - April 23rd, 2018
- Low T-Helper (CD4) Cell Level - Symptoms and Diagnosis - March 2nd, 2018
- ED Clinic Nashville TN, Erectile Dysfunction Treatment, Low T - February 10th, 2018
- Low-Testosterone (Low-T) - Controversy Over ... - AARP - January 11th, 2018
- Low testosterone symptoms | Effects of low testosterone - January 11th, 2018
- About Low Testosterone | Low T Center - December 29th, 2017
- Low Testosterone Replacement Therapy | Low T ... - Men's T Clinic - November 12th, 2017
- low t | eBay - November 12th, 2017
- Low Testosterone (Low T) Treatments - onhealth.com - November 2nd, 2017
- Low-T (Low Testosterone) Quiz: Symptoms, Signs & Treatment - October 22nd, 2017
- Erectile Dysfunction/Low T Men's Health Georgia - September 4th, 2017
- 10 easy ways to transform old band T-shirts into something new - Alternative Press - August 30th, 2017
- AbbVie Hit With $150 Million Loss in Low-T Cardiac Trial - Lexology (registration) - August 19th, 2017
- Low T Center returning to sponsor Sorenson - ESPN - August 18th, 2017
- Older men with 'low T' can improve their sex lives with testosterone therapy, study says - Men's Fitness - August 18th, 2017
- Center for Men | Tulsa Men's Clinic | Tulsa Low T - August 17th, 2017
- `Make Men Great Again' Speakers Bash Trans People While Pumping Up America's Girly Men - Southern Poverty Law Center - August 10th, 2017
- Doctors Address Low Testosterone Ads - CBS St. Louis - August 9th, 2017
- Low T - Testosterone Replacement Therapy - Ehormones - August 2nd, 2017
- What does a low T cell count mean? DoctorNDTV Queries - August 2nd, 2017
- Column: Testosterone treatment reserved for men with symptoms ... - The Daily Courier - July 5th, 2017
- Testosterone treatment reserved for men with symptoms - Sarasota Herald-Tribune - July 5th, 2017
- Low T Trial: Testosterone Gel Increases Plaque in Arteries - DrugWatch.com - June 2nd, 2017